Cerevance
Boston, US Β· Founded 2016 Β· 31 employees on LinkedIn Β· 9 known investors
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples. The company has multiple candidates in clinical development targeting Parkinson's disease, psychiatric conditions, ALS, and Alzheimer's disease.
Founders & leadership
Investors Β· 9
Foresite Capitalβ verifiedWest Hollywood
GV (Google Ventures)β verifiedMountain View Β· $250K β $50M
Dementia Discovery Fundβ verifiedLondon
SV Life Sciencesβ verifiedBoston
Dementia DiscoveryLondon
Lightstone VenturesPortola Valley
SV Health InvestorsBoston Β· $1M β $20M
Agent CapitalreportedWaltham
Dolby Family VenturesreportedSan Francisco
Frequently asked questions
- What does Cerevance do?
- Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples. The company has multiple candidates in clinical development targeting Parkinson's disease, psychiatric conditions, ALS, and Alzheimer's disease.
- Who are Cerevance's investors?
- Cerevance's investors include Foresite Capital, GV (Google Ventures), Dementia Discovery Fund, SV Life Sciences, Dementia Discovery, Lightstone Ventures, SV Health Investors, Agent Capital and 1 more.
- Where is Cerevance headquartered?
- Cerevance is headquartered in Boston, US.